Multiaction Pt(IV)
prodrugs can overcome resistance associated with the FDA approved Pt(II) drugs like
cisplatin. Intracellular reduction of the octahedral Pt(IV) derivatives of
cisplatin releases
cisplatin and the two axial
ligands. When the released axial
ligands act synergistically with
cisplatin to kill the
cancer cells, we have multiaction
prodrugs. Most Pt(IV) multiaction
prodrugs have bioactive
ligands possessing a carboxylate that is conjugated to the Pt(IV) because breaking the Pt(IV)-
ligand bond releases the active moiety. As many drugs that act synergistically with
cisplatin do not have carboxylates, a major challenge is to prepare multiaction Pt(IV) complexes with drugs that have amino groups or
hydroxyl groups such that following reduction, the drugs are released in their active form. Our objective was to prepare multiaction Pt(IV)
prodrugs that release bioactive molecules having amino groups. Because we cannot conjugate amino groups to the axial position of Pt(IV), we developed a novel and efficient approach for the synthesis of Pt(IV)-carbamato complexes and demonstrated that following reduction of the Pt(IV), the released
carbamates undergo rapid decarboxylation, releasing the free
amine, as in the case of the PARP-1 inhibitor
3-aminobenzamide and the amino derivative of the
HDAC inhibitor SAHA. Pt(IV)-carbamato complexes are stable in cell culture medium and are reduced by ascorbate. They are reduced slower than their carboxylato and carbonato analogues. We believe that this approach paves the way for preparing novel classes of multiaction Pt(IV)
prodrugs with amino containing bioactive molecules that up to now were not accessible.